PTCISB/08s (08-03)
Approved for use through 07/31/2008 ONB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless of contains a valid OMB control number.

Remove

VAI.P035NP

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1 99)

Application Number 10595087

Filing Date
First Named Inventor |
Art Unit |
Examiner Name |

Attorney Docket Number

U.S.PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant s Appear
	1	6084513					
	2	6703935					
	3	6617963					
If you wisi	h to a	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant s Appear
		Publication Number				Releva	nt Passages or Relevant
	No					Releva	nt Passages or Relevant
	No 1	20040008123				Releva	nt Passages or Relevant

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date	
	First Named Inventor	
(Not for submission under 37 CFR 1.99)	Art Unit	
(Not for Submission and or or it issay	Examiner Name	
	Attorney Docket Number	VALP035NP
\		
If you wish to add additional U.S. Published Ap	polication eitation information of	lease click the Add button Add
ii you wish to add additional o.o. Published Ap	ppication ciation information p	lease click the Add button, Add

10595087

Annlication Number

FOREIGN PATENT DOCUMENTS Remove								
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	02083507	wo					
	2	01069525	wo					

If you wish to add additional Foreign Patent Document citation information please click the Add button Add NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Cite Initials*

Cite Initials*

Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item book, magazine, journal, serial, symposium, catalog, etc), date, pages(e), volume-issue number(e), publisher, city andor country where published.

Examiner Cite | Chook, registaries, journal, serial, symposium, catalog, etc), date, pages(s), volume-lesse number(s), publisher, dity and/or country where published.

If you wish to add additional non-patent literature document citation information please click the Add button | Add |

EXAMINER SIGNATURE |

Examiner Signature		Date Considered				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a						

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Knd Codes of USPTO Patent Documents at year USPTO_GOV or MPTP 901.04. 2 Enter office that resued the document, by the low-letter code (WIPO Standard ST3). 2 For Japanese patent occurrent, by the low-letter code (WIPO Standard ST3). 2 For Japanese patent occurrent, be reducised or the year of the erigin of the Emperor man precise the event number of the patent cocurrent. When of concurrent the accountains to their accountain to their occurrent them.

English language translation is attached.

Date		
lamed Inventor	•	
it		
ner Name		
ey Docket Number	VALP035NP	
	iner Name ey Docket Number	iner Name

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s	Please see	37	CFR 1.97	and	1.98	to make	the	appropriate	selection(s	į
---	------------	----	----------	-----	------	---------	-----	-------------	-------------	---

INFORMATION DISCLOSUR STATEMENT BY APPLICAN (Not for submission under 37 CFR 1 99

That each item of information contained in the information disclosure statement was first cited in any communication \overline{M} from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

OR

VA 22313-1450

- That no item of Information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement.
 - See attached certification statement.
 - Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USFTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR application from the USFTO. The will vary depending upon the instituted case. Any comments on the amount of time your require to complete this form and/or suggestions for reducing this burde, should be sent to the Chef Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO INSADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, P.O. Box 1450, P.O. Box 1450,

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is SU U.S. C. (2)(2)(2) (2) famishing of the information solicide is voluntary, and (3) the principal purpuses for which the information is used by the U.S. Patient and Trademan Kolline is to process another examines your submission related to a patient application or patient. If you do not furnish the requested process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission related to a patient application or patient. If you do not furnish the requested the process another examines your submission, which may related the process and/or examines your submission, which may related the process and/or examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disease records.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, oursuant to 5 U.S. C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, cuting an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make indemninations a partial individuals.
 - 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuance of a patient pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1-14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.